Brief: Atea Pharma Announces Positive Initial Data From Phase 2 Study For Hepatitis C Virus (HCV)

Atea Pharmaceuticals

08/01/2024 21:57

Jan 8 (Reuters) - Atea Pharmaceuticals Inc  AVIR.O :
    * ATEA PHARMACEUTICALS ANNOUNCES POSITIVE INITIAL DATA FROM
PHASE
2 STUDY FOR HEPATITIS C VIRUS (HCV) AND SIGNIFICANT ENROLLMENT
MILESTONE FOR PHASE 3 SUNRISE-3 TRIAL FOR COVID-19
    * ATEA PHARMACEUTICALS INC - FIRST INTERIM ANALYSIS BY
INDEPENDENT
DATA SAFETY MONITORING BOARD (DSMB) EXPECTED IN MARCH 2024
    * ATEA PHARMACEUTICALS INC - PHASE 3 SUNRISE-3 ENROLLMENT
SURPASSED 650 PATIENTS IN MONOTHERAPY ARM
    * ATEA PHARMACEUTICALS INC:  FULL ENROLLMENT OF FOR HCV
COMBINATION STUDY EXPECTED TO BE COMPLETED BY MID-2024 WITH
TOPLINE RESULTS IN Q3 OF 2024.

Source text for Eikon:  ID:nGNXcbN92Y 
Further company coverage:  AVIR.O 

 ((Reuters.Briefs@thomsonreuters.com;))